Peric Barbara, Cerkovnik Petra, Novakovic Srdjan, Zgajnar Janez, Besic Nikola, Hocevar Marko
Department of Surgical Oncology, Institute of Oncology Ljubljana, Zaloska 2, SI-1000, Ljubljana, Slovenia.
BMC Med Genet. 2008 Sep 19;9:86. doi: 10.1186/1471-2350-9-86.
Two high-risk genes have been implicated in the development of CM (cutaneous melanoma). Germline mutations of the CDKN2A gene are found in < 25% of melanoma-prone families and there are only seven families with mutation of the CDK4 gene reported to date. Beside those high penetrance genes, certain allelic variants of the MC1R gene modify the risk of developing the disease.
to determine the prevalence of germline CDKN2A mutations and variants in members of families with familial CM and in patients with multiple primary CM; to search for possible CDK4 mutations, and to determine the frequency of variations in the MC1R gene.
From January 2001 until January 2007, 64 individuals were included in the study. The group included 28 patients and 7 healthy relatives belonging to 25 families, 26 patients with multiple primary tumors and 3 children with CM. Additionally 54 healthy individuals were included as a control group. Mutations and variants of the melanoma susceptibility genes were identified by direct sequencing.
Seven families with CDKN2A mutations were discovered (7/25 or 28.0%). The L94Q mutation found in one family had not been previously reported in other populations. The D84N variant, with possible biological impact, was discovered in the case of patient without family history but with multiple primary CM. Only one mutation carrier was found in the control group. Further analysis revealed that c.540C>T heterozygous carriers were more common in the group of CM patients and their healthy relatives (11/64 vs. 2/54). One p14ARF variant was discovered in the control group and no mutations of the CDK4 gene were found. Most frequently found variants of the MC1R gene were T314T, V60L, V92M, R151C, R160W and R163Q with frequencies slightly higher in the group of patients and their relatives than in the group of controls, but the difference was statistically insignificant.
The present study has shown high prevalence of p16INK4A mutations in Slovenian population of familial melanoma patients (37%) and an absence of p14ARF or CDK4 mutations.
两种高风险基因与皮肤黑色素瘤(CM)的发生有关。在不到25%的黑色素瘤易感家族中发现了CDKN2A基因的种系突变,迄今为止仅报道了7个携带CDK4基因突变的家族。除了这些高外显率基因外,MC1R基因的某些等位基因变异也会改变患该病的风险。
确定家族性CM家族成员和多发性原发性CM患者中种系CDKN2A突变和变异的患病率;寻找可能的CDK4突变,并确定MC1R基因变异的频率。
从2001年1月至2007年1月,64人被纳入研究。该组包括属于25个家族的28名患者和7名健康亲属、26名多发性原发性肿瘤患者以及3名CM患儿。另外54名健康个体作为对照组。通过直接测序鉴定黑色素瘤易感基因的突变和变异。
发现7个携带CDKN2A突变的家族(7/25或28.0%)。在一个家族中发现的L94Q突变此前在其他人群中未曾报道。在一名无家族史但有多发性原发性CM的患者中发现了可能具有生物学影响的D84N变异。在对照组中仅发现一名突变携带者。进一步分析显示,c.540C>T杂合携带者在CM患者及其健康亲属组中更为常见(11/64 vs. 2/54)。在对照组中发现了一个p14ARF变异,未发现CDK4基因的突变。MC1R基因最常见的变异是T314T、V60L、V92M、R151C、R160W和R163Q,其在患者及其亲属组中的频率略高于对照组,但差异无统计学意义。
本研究表明,斯洛文尼亚家族性黑色素瘤患者群体中p16INK4A突变的患病率较高(37%),且不存在p14ARF或CDK4突变。